QIAGEN Adds dPCR Platform QIAcuity to Growing Portfolio of COVID-19 Testing Solutions for Wastewater and Mutation Testing
January 28 2021 - 4:05PM
Business Wire
- Digital PCR for COVID-19 wastewater testing overcomes
limitations of traditional PCR
- Wastewater surveillance testing can quantify COVID-19 in
populations and track mutations
- Custom QIAcuity One-Step Viral RT-PCR Kit supports wastewater
testing applications
QIAGEN today announced the addition of kits for wastewater
testing to its growing portfolio of COVID-19 products. The use of
dPCR in the worldwide surveillance of COVID-19 is an additional
step towards making digital PCR (dPCR) an affordable and standard
instrument for a host of applications in molecular-testing
laboratories worldwide.
The new kits are designed for use on the uniquely fast and
easy-to-use series of QIAcuity instruments based on digital
polymerase chain reaction (dPCR) technology. QIAcuity precisely
quantifies even minimal quantities of DNA and RNA in research tests
for viruses, bacteria or genetic disorders, including the rarest of
cancer mutations.
The precision of QIAcuity provides a valuable tool for use in
testing wastewater for SARS-CoV-2. The application offers a
cost-effective way to survey transmission dynamics of entire
communities, avoiding the biases of other epidemiological
indicators like deaths as a proportion of known cases or of the
total population.
"In a trial run with the new high-throughput QIAcuity Eight, we
were able to successfully detect new variants of SARS-CoV-2 in
wastewater samples," said Dr. Franz Durandet, President of I.A.G.E.
in Montpellier, France. "Our tests have proven that this fast and
scalable technology from QIAGEN can provide a valuable addition to
our environmental biological testing services, which we will offer
to our clients in the near future."
COVID-19 surveillance through wastewater testing allows public
authorities to collect data from broad sweeps of the population,
including people who do not feature in public-health statistics
because they lack access to healthcare. Potentially, surveillance
testing can reveal infection and mutation dynamics earlier than
diagnostic testing, providing public-health officials with
near-real-time information on disease prevalence.
Please find the full press release here
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210128006080/en/
QIAGEN Investor Relations John Gilardi +49 2103 29
11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com Public
Relations Thomas Theuringer +49 2103 29 11826 Robert Reitze +49
2103 29 11676 e-mail: pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024